Free Light Chains & Monoclonal Gammopathies
Impact on Diagnostic Panels
Uses of Serum Free Light Chain Assay
August 2008
So if we include the serum free light chain assay as part of the initial diagnostic screen, how will we use it?
Well obviously it becomes part of our diagnostic panel and association with PEL and IFE. In addition, although I haven’t talked about this, baseline values of the free light chain assay have been shown to have prognostic value for predicting progression in patients with MGUS and smoldering myeloma, as well as for overall survival, in patients with multiple myeloma, plasmacytoma & primary amyloidosis. And lastly, in patients with no M-spike, it can be used to monitor therapy and disease course.
Uses of Serum Free Light Chain Assay |
Jump to section:
- Introduction
- Diagnostic Tests
- Mayo Clinic 1960-2003
- Plasma Cell Proliferative Disorders
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Monoclonal Serum Proteins: Newly Diagnosed Multiple Myeloma (n=1027)
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Urine Protein Electrophoresis & Immunofixation Electrophoresis
- Intact Immunoglobulin/Free Light Chain
- FLC Reference Range
- Diagnoses for 428 Patients Selected for Urine Monoclonal Protein
- Serum PEL & IFE Results: 428 Pts with Urine Monoclonal Protein
- Laboratory Results: 428 Patients with Monoclonal Urinary Protein
- Potential Savings
- Uses of Serum Free Light Chain Assay
- Diagnostic Test Panel for Suspected Monoclonal Gammopathies
- Questions?
External
link
PDF
document
Excel
document
Word
document